CRITERIA FOR DESTABILIZATION OF THE DISEASE COURSE IN PATIENTS WITH CORONARY HEART DISEASE

Authors:

Abstract:

173 patients with various coronary heart disease course variants were examined to identify possible pathogenetically based criteria for destabilization of the disease course. It was established that patients with an unstable course of coronary heart disease were characterized by both more pronounced inflammatory reaction and impairment of vascular endothelial function. Inflammatory activation was evidenced by a significant increase in biochemical markers of inflammation: high-sensitivity C-reactive protein and tumor necrosis factor-α – not only relative to the control group, but also to patients with stable coronary artery disease. The same differences were observed about endothelial dysfunction that was evidenced by a significant increase in its biochemical markers (ET-1, sVCAM, and PAPP-A). Therefore, such markers can be considered as criteria for destabilizing of the atherosclerotic process.

Keywords:

coronary heart disease nonspecific systemic inflammation endothelial dysfunction hyperleptinemia dyslipidemia

References:

1. Botts SR, Fish JE, Howe KL. Dysfunctional vascular endothelium as a driver of atherosclerosis: Emerging insights into pathogenesis and treatment. Frontiers in Pharmacology. 2021;12. doi:10.3389/fphar.2021.787541
2. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357–418. doi: https://doi.org/10.1124/pr. 115.011833
3. De Caterina R, D'Ugo E, Libby P. Inflammation and thrombosis – testing the hypothesis with anti-inflammatory drug trials. Thrombosis and Haemostasis. 2016;116(12):1012–21. doi: 10.1160/th16-03-0246
4. Gregersen I, Halvorsen B. Inflammatory mechanisms in atherosclerosis. Atherosclerosis – Yesterday, Today and Tomorrow. 2018; chapter 3. doi: 10.5772/intechopen.72222
5. Hui H, Feng T. Adipose tissue as an endocrine organ. Adipose Tissue. 2018. DOI 10.5772/intechopen.76220
6. Jankowich M, Choudhary G. Endothelin-1 levels and cardiovascular events. Trends in Cardiovascular Medicine. 2020;30(1):1–8. doi: 10.1016/j.tcm.2019.01.007
7. Kuzminova N, Romanova V, Serkova V, Osovska N, Kniazkova I. Inflammation indicators and leptin level in patients with ischemic heart disease. Lekarsky Obzor; 2016; 65(6):140–5
8. Kwon OC, Park M-C. Effect of tumor necrosis factor inhibitors on the risk of cardiovascular disease in patients with axial spondyloarthritis. Arthritis Research & Therapy. 2022;24(1). doi:10.1186/s13075-022-02836-4
9. Lindstrom M, DeCleene N, Dorsey H, et al. Global Burden of Cardiovascular Disease and Risks Collaboration, 1990-2021. J Am Coll Cardiol. 2022 Dec, 80(25) 2372–2425
10. Parveen N, Subhakumari KN, Krishnan S. Pregnancy associated plasma protein-A (PAPP-A) levels in acute coronary syndrome: A case control study in a tertiary care center. Indian Journal of Clinical Biochemistry. 2014;30(2):150–4 doi: 10.1007/s12291-014-0421-9
11. Poetsch MS, Strano A, Guan K. Role of leptin in cardiovascular diseases. Frontiers in Endocrinology. 2020;11. doi:10.3389/fendo.2020.00354
12. Shaposhnyk OA, Prykhodko NP, Savchenko LV, Shevchenko TI, Sorokina SI, Yakymyshyna LI et al. Clinical and diagnostic aspects of managing patients with valvular heart disease. World of medicine and biology 2022; 2(80):178–183. doi: 10.26724/2079-8334-2022-2-80-178-183
13. Troncoso MF, Ortiz-Quintero J, Garrido-Moreno V, Sanhueza-Olivares F, Guerrero-Moncayo A, Chiong M, et al. VCAM-1 as a predictor biomarker in cardiovascular disease. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2021;1867(9):166170. doi: 10.1016/j.bbadis.2021.166170
14. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: From mechanism to pharmacotherapies. Pharmacological Reviews. 2021;73(3):924–67. doi: 10.1124/pharmrev. 120.000096
15. Yuan S, Carter P, Bruzelius M, Vithayathil M, Kar S, Mason AM, et al. Effects of tumor necrosis factor on cardiovascular disease and cancer: A two- sample mendelian randomization study. eBioMedicine. 2020; 59:102956. doi: 10.1016/j.ebiom.2020.102956

Publication:

«World of Medicine and Biology» Vol. 19 No. 86 (2023) , с. 129-132
УДК 616.13-002:616.12-005.4-08

DOI:

https://doi.org/10.26724/2079-8334-2023-4-86-129-132